D013882Chemicals & DrugsD02.845.746.703D02.886.803660.99878Thiosemicarbazonesprns:emailEncryptedemail addressprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentvivo:hrJobTitleHR job titleInformation ResourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson29614828Azam M, Al-Resayes SI, Wabaidur SM, Altaf M, Chaurasia B, Alam M, Shukla SN, Gaur P, Albaqami NTM, Islam MS, Park SMolecules (Basel, Switzerland)Synthesis, Structural Characterization and Antimicrobial Activity of Cu(II) and Fe(III) Complexes Incorporating Azo-Azomethine Ligand. Molecules. 2018 Apr 02; 23(4).Molecules2018-04-02T00:00:002018Synthesis, Structural Characterization and Antimicrobial Activity of Cu(II) and Fe(III) Complexes Incorporating Azo-Azomethine Ligand.Medicine-Hematology and Oncology18217206Odenike OM, Larson RA, Gajria D, Dolan ME, Delaney SM, Karrison TG, Ratain MJ, Stock WInvestigational new drugsPhase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia. Invest New Drugs. 2008 Jun; 26(3):233-9.Invest New Drugs2008-01-24T00:00:002008Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia.Public Health Sciences0.08135890.02033976research area of0.6601920.08145823subject area forUniversity of ChicagoRichard A.LarsonRichard A. Larson41.78927490000000-87.601250000000001169Larson, Richard A.ProfessorMark J.RatainMark J. Ratain41.78927490000000-87.601250000000001401Ratain, Mark J.ProfessorWendyStockwHF9BKIeOfnamXNnYUHhvWD+6g==Wendy Stock41.78927490000000-87.601250000000001502Stock, WendyProfessorTheodoreKarrisonTheodore Karrison41.78927490000000-87.601250000000002356Karrison, TheodoreResearch ProfessorOlatoyosiOdenikew21tDq8cEun5hHlsaUXv9Gq0+s+oOlatoyosi Odenike41.78927490000000-87.60125000000000399Odenike, OlatoyosiProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1Research ProfessorResearch Professor19176392Rao VA, Klein SR, Agama KK, Toyoda E, Adachi N, Pommier Y, Shacter EBCancer researchThe iron chelator Dp44mT causes DNA damage and selective inhibition of topoisomerase IIalpha in breast cancer cells. Cancer Res. 2009 Feb 01; 69(3):948-57.Cancer Res2009-01-27T00:00:002009The iron chelator Dp44mT causes DNA damage and selective inhibition of topoisomerase IIalpha in breast cancer cells.